Aralex Pharmaceuticals’ U.S. and Ireland-based subsidiaries, as well as the company’s Canadian debtors, filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of New York.